Acamprosate

NERVOUS SYSTEM

Key facts

Acamprosate is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 2004. DrugCentral lists 2 molecular targets, including GABRA1|GABRG2|GABRB3 and GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A. Recorded indications include Alcoholism.

• Approval status: ofp (first approved 2004 by the FDA).
• Molecular targets: GABRA1|GABRG2|GABRB3 and GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A (2 listed in DrugCentral).
• Indications: Alcoholism.
• ATC code: N07BB03 (Drugs used in alcohol dependence).
• Molecular formula: C5H11NO4S; molecular weight 181.21 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Alcoholism

Contraindications (3)

• Acute nephropathy
• Impaired renal function disorder
• Suicidal thoughts

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
GABA-A receptor alpha-1/beta-3/gamma-2	GABRA1|GABRG2|GABRB3	other	—
Glutamate [NMDA] receptor	GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A	antagonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2004-07-29	FDA	—	FOREST LABS

ATC classification

ATC code	Therapeutic hierarchy
N07BB03	NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › DRUGS USED IN ADDICTIVE DISORDERS › Drugs used in alcohol dependence

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Electrocardiogram QT prolonged	116.8
Ventricular fibrillation	82.6
Intentional overdose	77.9
Overdose	76.7
Anticoagulation drug level above therapeutic	70.9
Torsade de pointes	68.5
Alcoholism	67.5
Coma	67.4
Intentional self-injury	65.2
Hepatitis acute	52.6
Delirium	42.2
Hyperhidrosis	41.7

Chemical structure

• Molecular formula: C₅H₁₁NO₄S
• Molecular weight: 181.21 g/mol
• CAS number: 77337-76-9
• InChIKey: AFCGFAGUEYAMAO-UHFFFAOYSA-N
• PubChem CID: 71158

CC(=O)NCCCS(O)(=O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Acamprosate used for?

DrugCentral lists the following indications for Acamprosate: Alcoholism.

How does Acamprosate work?

Its molecular targets in DrugCentral include GABRA1|GABRG2|GABRB3 and GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A (antagonist).

When was Acamprosate first approved?

Acamprosate was first approved by the FDA in 2004.

What is the chemical formula of Acamprosate?

Acamprosate has the molecular formula C5H11NO4S and a molecular weight of 181.21 g/mol.

Sources

• DrugCentral drug card 38 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201293 — compound record and bioactivity
• PubChem CID 71158 — chemical identifiers
• DrugBank DB00659 — drug record
• FDA UNII N4K14YGM3J — substance identity
• DailyMed: FDA labels for Acamprosate — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.